<\/p>\n
Rioci 1<\/strong> is 1 mg riociguat tablets from a WHO-GMP certified manufacturer — a soluble guanylate cyclase (sGC) stimulator for \u03c0\u03bd\u03b5\u03c5\u03bc\u03bf\u03bd\u03b9\u03ba\u03ae \u03b1\u03c1\u03c4\u03b7\u03c1\u03b9\u03b1\u03ba\u03ae \u03c5\u03c0\u03ad\u03c1\u03c4\u03b1\u03c3\u03b7 (PAH)<\/strong>. \u0397 PAH \u03b5\u03af\u03bd\u03b1\u03b9 \u03bc\u03b9\u03b1 \u03c3\u03c5\u03b3\u03ba\u03b5\u03ba\u03c1\u03b9\u03bc\u03ad\u03bd\u03b7, \u03c0\u03c1\u03bf\u03bf\u03b4\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u03ba\u03b1\u03b9 \u03c3\u03c0\u03ac\u03bd\u03b9\u03b1 \u03bd\u03cc\u03c3\u03bf\u03c2 \u2014 \u03b4\u03b5\u03bd \u03b5\u03af\u03bd\u03b1\u03b9 \u03c4\u03bf \u03af\u03b4\u03b9\u03bf \u03bc\u03b5 \u03c4\u03b7 \u03c3\u03c5\u03c3\u03c4\u03b7\u03bc\u03b9\u03ba\u03ae \u03c5\u03c0\u03ad\u03c1\u03c4\u03b1\u03c3\u03b7<\/strong>. It raises pressure in the pulmonary arteries, not the systemic arteries, and requires dedicated specialist-directed therapy at an accredited PAH centre. Riociguat was introduced by Bayer in 2013 as Adempas<\/strong> — the first sGC stimulator approved for human use. FDA-approved for two specific forms of pulmonary hypertension: pulmonary arterial hypertension (PAH, WHO Group 1) and chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4) — the only oral drug approved for inoperable CTEPH. directly activates soluble guanylate cyclase (the NO receptor) in pulmonary arterial smooth muscle, raising cGMP and producing pulmonary vasodilation. Unlike PDE5 inhibitors, riociguat stimulates sGC even in the absence of NO, giving activity in NO-deficient vascular beds characteristic of PAH and CTEPH. Dosing: Start 1 mg three times daily (8-hour intervals); titrate every 2 weeks by 0.5 mg increments based on systolic BP (must remain >95 mmHg) and symptoms. Target dose 2.5 mg three times daily. PAH treatment is typically combination therapy initiated and monitored at a specialist centre; this is not a DIY disease.<\/p>\n<\/div>\n \ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n \u03a4\u03b1 \u03b3\u03b5\u03bd\u03cc\u03c3\u03b7\u03bc\u03b1 \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03ac \u03bc\u03b1\u03c2 \u03c0\u03c1\u03bf\u03ad\u03c1\u03c7\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ad\u03c2 \u03c0\u03bf\u03c5 \u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd WHO-GMP \u03ba\u03b1\u03b9 \u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03bd\u03c4\u03b1\u03b9 \u03c0\u03b1\u03b3\u03ba\u03bf\u03c3\u03bc\u03af\u03c9\u03c2 \u03c3\u03b5 \u03b4\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae, \u03b1\u03c0\u03bb\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u2014 \u03c7\u03c9\u03c1\u03af\u03c2 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5 \u03c3\u03c4\u03bf \u03b5\u03be\u03c9\u03c4\u03b5\u03c1\u03b9\u03ba\u03cc \u03c4\u03bf\u03c5 \u03b4\u03ad\u03bc\u03b1\u03c4\u03bf\u03c2. \u039f\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u03b4\u03c1\u03bf\u03bc\u03bf\u03bb\u03bf\u03b3\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03bc\u03ad\u03c3\u03c9 \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf\u03c5 \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae (\u03bf\u03b9 \u03c0\u03b5\u03c1\u03b9\u03b3\u03c1\u03b1\u03c6\u03ad\u03c2 \u03b5\u03ba\u03ba\u03b1\u03b8\u03ac\u03c1\u03b9\u03c3\u03b7\u03c2 \u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03bf\u03c5\u03bd \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ce\u03bd \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u2014 \u03c0\u03bf\u03c4\u03ad \u201cMedsBase\u201d \u03ae \u03bf\u03c0\u03bf\u03b9\u03bf\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5). \u0393\u03af\u03bd\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b4\u03b5\u03ba\u03c4\u03ad\u03c2 \u03ba\u03b1\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03c1\u03c5\u03c0\u03c4\u03bf\u03bd\u03bf\u03bc\u03af\u03c3\u03bc\u03b1\u03c4\u03b1 \u03ba\u03b1\u03b9 \u03c4\u03c1\u03b1\u03c0\u03b5\u03b6\u03b9\u03ba\u03ae \u03bc\u03b5\u03c4\u03b1\u03c6\u03bf\u03c1\u03ac SEPA. \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2 \u0395\u03be\u03b1\u03c3\u03c6\u03b1\u03bb\u03af\u03c3\u03b5\u03ce\u03c2 \u03bc\u03b1\u03c2.<\/p>\n Rioci 1 is 1 mg riociguat tablets from a WHO-GMP certified manufacturer, supplied in 10-180 tablets. Riociguat was introduced by Bayer in 2013 as Adempas<\/strong> — the first sGC stimulator approved for human use. FDA-approved for two specific forms of pulmonary hypertension: pulmonary arterial hypertension (PAH, WHO Group 1) and chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4) — the only oral drug approved for inoperable CTEPH.<\/p>\n \u0397 \u03c0\u03bd\u03b5\u03c5\u03bc\u03bf\u03bd\u03b9\u03ba\u03ae \u03b1\u03c1\u03c4\u03b7\u03c1\u03b9\u03b1\u03ba\u03ae \u03c5\u03c0\u03ad\u03c1\u03c4\u03b1\u03c3\u03b7 (PAH) \u03b4\u03b5\u03bd \u03b5\u03af\u03bd\u03b1\u03b9 \u03c3\u03c5\u03c3\u03c4\u03b7\u03bc\u03b1\u03c4\u03b9\u03ba\u03ae \u03c5\u03c0\u03ad\u03c1\u03c4\u03b1\u03c3\u03b7.<\/strong> \u0397 PAH \u03b1\u03bd\u03b1\u03c6\u03ad\u03c1\u03b5\u03c4\u03b1\u03b9 \u03c3\u03c5\u03b3\u03ba\u03b5\u03ba\u03c1\u03b9\u03bc\u03ad\u03bd\u03b1 \u03c3\u03b5 \u03b1\u03c5\u03be\u03b7\u03bc\u03ad\u03bd\u03b7 \u03c0\u03af\u03b5\u03c3\u03b7 \u03c3\u03c4\u03b7\u03bd \u03c0\u03bd\u03b5\u03c5\u03bc\u03bf\u03bd\u03b9\u03ba\u03ae \u03b1\u03c1\u03c4\u03b7\u03c1\u03b9\u03b1\u03ba\u03ae \u03ba\u03c5\u03ba\u03bb\u03bf\u03c6\u03bf\u03c1\u03af\u03b1 (\u226520 mmHg \u03bc\u03ad\u03c3\u03b7 \u03c0\u03bd\u03b5\u03c5\u03bc\u03bf\u03bd\u03b9\u03ba\u03ae \u03b1\u03c1\u03c4\u03b7\u03c1\u03b9\u03b1\u03ba\u03ae \u03c0\u03af\u03b5\u03c3\u03b7 \u03bc\u03b5 \u03c0\u03bd\u03b5\u03c5\u03bc\u03bf\u03bd\u03b9\u03ba\u03ae \u03b1\u03b3\u03b3\u03b5\u03b9\u03b1\u03ba\u03ae \u03b1\u03bd\u03c4\u03af\u03c3\u03c4\u03b1\u03c3\u03b7 \u22652 \u03bc\u03bf\u03bd\u03ac\u03b4\u03b5\u03c2 Wood \u03c3\u03cd\u03bc\u03c6\u03c9\u03bd\u03b1 \u03bc\u03b5 \u03c4\u03b9\u03c2 \u03bf\u03b4\u03b7\u03b3\u03af\u03b5\u03c2 ESC\/ERS 2022). \u0395\u03af\u03bd\u03b1\u03b9 \u03c3\u03c0\u03ac\u03bd\u03b9\u03b1 (\u03b5\u03ba\u03c4\u03b9\u03bc\u03ce\u03bc\u03b5\u03bd\u03b7 \u03c3\u03c5\u03c7\u03bd\u03cc\u03c4\u03b7\u03c4\u03b1 15-50 \u03b1\u03bd\u03ac \u03b5\u03ba\u03b1\u03c4\u03bf\u03bc\u03bc\u03cd\u03c1\u03b9\u03bf \u03b5\u03bd\u03b7\u03bb\u03af\u03ba\u03c9\u03bd), \u03c0\u03c1\u03bf\u03bf\u03b4\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u03ba\u03b1\u03b9 \u03c7\u03c9\u03c1\u03af\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03ad\u03c7\u03b5\u03b9 \u03ba\u03b1\u03ba\u03ae \u03c0\u03c1\u03cc\u03b3\u03bd\u03c9\u03c3\u03b7 (\u03b9\u03c3\u03c4\u03bf\u03c1\u03b9\u03ba\u03ae \u03b5\u03c0\u03b9\u03b2\u03af\u03c9\u03c3\u03b7 5 \u03b5\u03c4\u03ce\u03bd \u223c30%). \u0397 \u03c3\u03cd\u03b3\u03c7\u03c1\u03bf\u03bd\u03b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03c0\u03bf\u03c5 \u03c3\u03c4\u03bf\u03c7\u03b5\u03cd\u03b5\u03b9 \u03c3\u03c4\u03b7\u03bd PAH \u03ad\u03c7\u03b5\u03b9 \u03b2\u03b5\u03bb\u03c4\u03b9\u03ce\u03c3\u03b5\u03b9 \u03c4\u03b7\u03bd \u03b5\u03c0\u03b9\u03b2\u03af\u03c9\u03c3\u03b7 5 \u03b5\u03c4\u03ce\u03bd \u03c3\u03b5 60-70% \u03c3\u03b5 \u03b5\u03b9\u03b4\u03b9\u03ba\u03ac \u03ba\u03ad\u03bd\u03c4\u03c1\u03b1.<\/p>\n Candidates for Rioci 1 have been diagnosed at a PAH specialist centre via right heart catheterisation, with WHO\/NYHA functional class II-IV symptoms and confirmed PAH (WHO Group 1) or — for riociguat — inoperable or persistent CTEPH (WHO Group 4). This is not a drug for ordinary hypertension or for self-initiated therapy.<\/p>\n Directly activates soluble guanylate cyclase (the NO receptor) in pulmonary arterial smooth muscle, raising cGMP and producing pulmonary vasodilation. Unlike PDE5 inhibitors, riociguat stimulates sGC even in the absence of NO, giving activity in NO-deficient vascular beds characteristic of PAH and CTEPH.<\/p>\n PATENT-1 (2013)<\/strong> — riociguat in 443 PAH patients; 6-minute walk distance improved by 30 m vs placebo, with better WHO functional class and delayed clinical worsening. CHEST-1 (2013)<\/strong> — riociguat in 261 inoperable or persistent CTEPH patients; 6-minute walk improved by 46 m vs placebo.<\/p>\n \u0394\u03bf\u03c3\u03bf\u03bb\u03bf\u03b3\u03af\u03b1:<\/strong> Start 1 mg three times daily (8-hour intervals); titrate every 2 weeks by 0.5 mg increments based on systolic BP (must remain >95 mmHg) and symptoms. Target dose 2.5 mg three times daily.<\/p>\n \u03a0\u03b1\u03c1\u03b1\u03ba\u03bf\u03bb\u03bf\u03cd\u03b8\u03b7\u03c3\u03b7:<\/strong> \u03c3\u03c4\u03b7 \u03b2\u03b1\u03c3\u03b9\u03ba\u03ae \u03b3\u03c1\u03b1\u03bc\u03bc\u03ae \u03ba\u03b1\u03b9 \u03ba\u03ac\u03b8\u03b5 3-6 \u03bc\u03ae\u03bd\u03b5\u03c2 \u03c3\u03c4\u03b7 \u03c3\u03c5\u03bd\u03ad\u03c7\u03b5\u03b9\u03b1 \u2014 \u03bb\u03b5\u03b9\u03c4\u03bf\u03c5\u03c1\u03b3\u03b9\u03ba\u03ae \u03ba\u03b1\u03c4\u03b7\u03b3\u03bf\u03c1\u03af\u03b1 WHO, \u03b1\u03c0\u03cc\u03c3\u03c4\u03b1\u03c3\u03b7 6-\u03bb\u03b5\u03c0\u03c4\u03bf\u03c5 \u03c0\u03b5\u03c1\u03b9\u03c0\u03ac\u03c4\u03bf\u03c5, NT-proBNP, \u03b5\u03c0\u03b1\u03bd\u03b1\u03bb\u03b7\u03c0\u03c4\u03b9\u03ba\u03ae \u03b7\u03c7\u03bf\u03ba\u03b1\u03c1\u03b4\u03b9\u03bf\u03b3\u03c1\u03b1\u03c6\u03af\u03b1 \u03ba\u03b1\u03b9 (\u03c3\u03b5 \u03bc\u03b5\u03b3\u03b1\u03bb\u03cd\u03c4\u03b5\u03c1\u03b1 \u03b4\u03b9\u03b1\u03c3\u03c4\u03ae\u03bc\u03b1\u03c4\u03b1) \u03ba\u03b1\u03b8\u03b5\u03c4\u03b7\u03c1\u03b9\u03b1\u03c3\u03bc\u03cc\u03c2 \u03b4\u03b5\u03be\u03b9\u03ac\u03c2 \u03ba\u03b1\u03c1\u03b4\u03b9\u03ac\u03c2. \u038c\u03bb\u03b1 \u03b3\u03af\u03bd\u03bf\u03bd\u03c4\u03b1\u03b9 \u03bc\u03ad\u03c3\u03c9 \u03b5\u03be\u03b5\u03b9\u03b4\u03b9\u03ba\u03b5\u03c5\u03bc\u03ad\u03bd\u03bf\u03c5 \u03ba\u03ad\u03bd\u03c4\u03c1\u03bf\u03c5 \u03a0\u0391\u03a5.<\/p>\n BP monitoring:<\/strong> systolic BP must remain >95 mmHg; uptitration paused or reversed on symptomatic hypotension.<\/p>\n \u038c\u03c7\u03b9. \u0397 \u03c3\u03c5\u03c3\u03c4\u03b7\u03bc\u03b1\u03c4\u03b9\u03ba\u03ae \u03c5\u03c0\u03ad\u03c1\u03c4\u03b1\u03c3\u03b7 \u03b5\u03af\u03bd\u03b1\u03b9 \u03b1\u03c5\u03be\u03b7\u03bc\u03ad\u03bd\u03b7 \u03c0\u03af\u03b5\u03c3\u03b7 \u03c3\u03c4\u03b7 \u03b3\u03b5\u03bd\u03b9\u03ba\u03ae \u03ba\u03c5\u03ba\u03bb\u03bf\u03c6\u03bf\u03c1\u03af\u03b1 \u03ba\u03b1\u03b9 \u03b5\u03af\u03bd\u03b1\u03b9 \u03c0\u03bf\u03bb\u03cd \u03c3\u03c5\u03c7\u03bd\u03ae\u00b7 \u03b7 \u03a0\u0391\u03a5 \u03b5\u03af\u03bd\u03b1\u03b9 \u03b1\u03c5\u03be\u03b7\u03bc\u03ad\u03bd\u03b7 \u03c0\u03af\u03b5\u03c3\u03b7 \u03b5\u03b9\u03b4\u03b9\u03ba\u03ac \u03c3\u03c4\u03b7\u03bd \u03c0\u03bd\u03b5\u03c5\u03bc\u03bf\u03bd\u03b9\u03ba\u03ae \u03ba\u03c5\u03ba\u03bb\u03bf\u03c6\u03bf\u03c1\u03af\u03b1 \u03ba\u03b1\u03b9 \u03b5\u03af\u03bd\u03b1\u03b9 \u03c3\u03c0\u03ac\u03bd\u03b9\u03b1. \u0388\u03c7\u03bf\u03c5\u03bd \u03b4\u03b9\u03b1\u03c6\u03bf\u03c1\u03b5\u03c4\u03b9\u03ba\u03ad\u03c2 \u03b1\u03b9\u03c4\u03af\u03b5\u03c2, \u03b4\u03b9\u03b1\u03c6\u03bf\u03c1\u03b5\u03c4\u03b9\u03ba\u03bf\u03cd\u03c2 \u03b5\u03b9\u03b4\u03b9\u03ba\u03bf\u03cd\u03c2 (\u03b7 \u03c6\u03c1\u03bf\u03bd\u03c4\u03af\u03b4\u03b1 \u03c4\u03b7\u03c2 \u03a0\u0391\u03a5 \u03b3\u03af\u03bd\u03b5\u03c4\u03b1\u03b9 \u03c3\u03c5\u03bd\u03ae\u03b8\u03c9\u03c2 \u03b1\u03c0\u03cc \u03bf\u03bc\u03ac\u03b4\u03b5\u03c2 \u03c0\u03bd\u03b5\u03c5\u03bc\u03bf\u03bd\u03bf\u03bb\u03bf\u03b3\u03af\u03b1\u03c2\/\u03ba\u03b1\u03c1\u03b4\u03b9\u03bf\u03bb\u03bf\u03b3\u03af\u03b1\u03c2 \u03c3\u03b5 \u03c4\u03c1\u03b9\u03c4\u03bf\u03b2\u03ac\u03b8\u03bc\u03b9\u03b1 \u03ba\u03ad\u03bd\u03c4\u03c1\u03b1) \u03ba\u03b1\u03b9 \u03c0\u03bf\u03bb\u03cd \u03b4\u03b9\u03b1\u03c6\u03bf\u03c1\u03b5\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c6\u03b1\u03c1\u03bc\u03b1\u03ba\u03b5\u03c5\u03c4\u03b9\u03ba\u03ad\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b5\u03c2. \u0388\u03bd\u03b1 \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03bf \u03c0\u03bf\u03c5 \u03bc\u03b5\u03b9\u03ce\u03bd\u03b5\u03b9 \u03c4\u03b7 \u03c3\u03c5\u03c3\u03c4\u03b7\u03bc\u03b1\u03c4\u03b9\u03ba\u03ae \u03c0\u03af\u03b5\u03c3\u03b7 (ACEi, ARB, CCB, \u03b8\u03b5\u03b9\u03b1\u03b6\u03af\u03b4\u03b9\u03bf) \u03c3\u03c5\u03bd\u03ae\u03b8\u03c9\u03c2 \u03ad\u03c7\u03b5\u03b9 \u03bc\u03b9\u03ba\u03c1\u03ae \u03b5\u03c0\u03af\u03b4\u03c1\u03b1\u03c3\u03b7 \u03c3\u03c4\u03b7\u03bd \u03a0\u0391\u03a5.<\/p>\n \u0397 \u03a0\u0391\u03a5 \u03b5\u03af\u03bd\u03b1\u03b9 \u03bc\u03b9\u03b1 \u03c0\u03ac\u03b8\u03b7\u03c3\u03b7 \u03c0\u03bf\u03c5 \u03b4\u03b9\u03b1\u03c7\u03b5\u03b9\u03c1\u03af\u03b6\u03b5\u03c4\u03b1\u03b9 \u03b5\u03b9\u03b4\u03b9\u03ba\u03cc\u03c2 \u03bc\u03b5 \u03ad\u03bd\u03b1 \u03bc\u03bf\u03bd\u03c4\u03ad\u03bb\u03bf \u03b5\u03c0\u03b9\u03c4\u03ae\u03c1\u03b7\u03c3\u03b7\u03c2 \u03c0\u03bf\u03c5 \u03b2\u03b1\u03c3\u03af\u03b6\u03b5\u03c4\u03b1\u03b9 \u03c3\u03b5 \u03bc\u03b7\u03c4\u03c1\u03ce\u03bf \u03c3\u03c4\u03b9\u03c2 \u03c0\u03b5\u03c1\u03b9\u03c3\u03c3\u03cc\u03c4\u03b5\u03c1\u03b5\u03c2 \u03c7\u03ce\u03c1\u03b5\u03c2. \u03a4\u03b1 \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03b1 \u03b5\u03af\u03bd\u03b1\u03b9 \u03b1\u03ba\u03c1\u03b9\u03b2\u03ac, \u03ad\u03c7\u03bf\u03c5\u03bd \u03c3\u03c5\u03b3\u03ba\u03b5\u03ba\u03c1\u03b9\u03bc\u03ad\u03bd\u03b5\u03c2 \u03c0\u03b1\u03c1\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b5\u03c2 (\u03b9\u03b4\u03b9\u03b1\u03af\u03c4\u03b5\u03c1\u03b1 \u03b7\u03c0\u03b1\u03c4\u03bf\u03c4\u03bf\u03be\u03b9\u03ba\u03cc\u03c4\u03b7\u03c4\u03b1 \u03b3\u03b9\u03b1 \u03c4\u03b1 ERA \u03ba\u03b1\u03b9 \u03c5\u03c0\u03bf\u03c4\u03cc\u03bd\u03b7\u03c3\u03b7 \u03b3\u03b9\u03b1 \u03c4\u03bf\u03c5\u03c2 \u03b4\u03b9\u03b5\u03b3\u03ad\u03c1\u03c4\u03b5\u03c2 sGC) \u03ba\u03b1\u03b9 \u03b7 \u03c0\u03c1\u03bf\u03c3\u03b1\u03c1\u03bc\u03bf\u03b3\u03ae \u03c4\u03b7\u03c2 \u03b4\u03cc\u03c3\u03b7\u03c2 \u03b5\u03be\u03b1\u03c1\u03c4\u03ac\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03b4\u03b9\u03b1\u03b4\u03bf\u03c7\u03b9\u03ba\u03ad\u03c2 \u03b1\u03be\u03b9\u03bf\u03bb\u03bf\u03b3\u03ae\u03c3\u03b5\u03b9\u03c2 (6-\u03bb\u03b5\u03c0\u03c4\u03bf \u03c0\u03b5\u03c1\u03c0\u03ac\u03c4\u03b7\u03bc\u03b1, \u03bb\u03b5\u03b9\u03c4\u03bf\u03c5\u03c1\u03b3\u03b9\u03ba\u03ae \u03c4\u03ac\u03be\u03b7, NT-proBNP, \u03b7\u03c7\u03bf\u03ba\u03b1\u03c1\u03b4\u03b9\u03bf\u03b3\u03c1\u03b1\u03c6\u03af\u03b1). \u0397 \u03b1\u03c5\u03c4\u03bf\u03b4\u03b9\u03b1\u03c7\u03b5\u03af\u03c1\u03b9\u03c3\u03b7 \u03b5\u03ba\u03c4\u03cc\u03c2 \u03b5\u03c4\u03b9\u03ba\u03ad\u03c4\u03b1\u03c2 \u03c3\u03c5\u03bd\u03b5\u03c0\u03ac\u03b3\u03b5\u03c4\u03b1\u03b9 \u03c5\u03c8\u03b7\u03bb\u03bf\u03cd\u03c2 \u03ba\u03b9\u03bd\u03b4\u03cd\u03bd\u03bf\u03c5\u03c2 \u03ba\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae\u03c2 \u03b5\u03c0\u03b9\u03b4\u03b5\u03af\u03bd\u03c9\u03c3\u03b7\u03c2.<\/p>\n \u038c\u03c7\u03b9 \u2014 \u03b1\u03c0\u03bf\u03bb\u03cd\u03c4\u03c9\u03c2 \u03b1\u03bd\u03c4\u03b5\u03bd\u03b4\u03b5\u03b9\u03ba\u03bd\u03cd\u03b5\u03c4\u03b1\u03b9.<\/strong> PDE5 inhibitors (sildenafil, tadalafil, vardenafil) combined with riociguat cause severe additive hypotension. If you need ED therapy, discuss alternatives with your PAH team; some PAH regimens use PDE5 inhibitors instead of riociguat as the pulmonary vasodilator.<\/p>\n \u038c\u03c7\u03b9.<\/strong> Embryofetal toxicity documented in animal studies; pregnancy testing and contraception required.<\/p>\n You can buy Rioci 1 (riociguat 1 mg, 10-180 tablets) from MedsBase with discreet packaging and worldwide shipping.<\/p>\n <\/p>\n \u0386\u03bb\u03bb\u03b1 \u03c0\u03c1\u03bf\u03ca\u03cc\u03bd\u03c4\u03b1 \u03c3\u03b5 \u03a7\u03c1\u03cc\u03bd\u03b9\u03b5\u03c2 \u03a0\u03b1\u03b8\u03ae\u03c3\u03b5\u03b9\u03c2<\/strong> \u03c0\u03bf\u03c5 \u03bf\u03b9 \u03c0\u03b5\u03bb\u03ac\u03c4\u03b5\u03c2 \u03b5\u03be\u03b5\u03c4\u03ac\u03b6\u03bf\u03c5\u03bd \u03b5\u03c0\u03af\u03c3\u03b7\u03c2:<\/p>\n Rioci 1 is riociguat 1 mg tablets \u2014 the first soluble guanylate cyclase (sGC) stimulator, originally Bayer Adempas (2013). Approved for pulmonary arterial hypertension (PAH, WHO Group 1) and the only oral drug for inoperable chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4). PATENT-1 and CHEST-1 trial evidence. Specialist-managed disease \u2014 not ordinary hypertension. Contraindicated with PDE5 inhibitors and nitrates.<\/p>","protected":false},"featured_media":60438,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3260,3356],"product_tag":[4861,4862],"class_list":{"0":"post-60437","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-heart-blood-pressure","9":"product_cat-high-blood-pressure-medication","10":"product_tag-rioci","11":"product_tag-riociguat","13":"first","14":"instock","15":"shipping-taxable","16":"purchasable","17":"product-type-variable","18":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product\/60437","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/comments?post=60437"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/media\/60438"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/media?parent=60437"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_brand?post=60437"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_cat?post=60437"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_tag?post=60437"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n
What Is Rioci 1?<\/h2>\n
How Riociguat Works<\/h2>\n
\u0391\u03c0\u03bf\u03b4\u03b5\u03b9\u03ba\u03c4\u03b9\u03ba\u03ac \u03a3\u03c4\u03bf\u03b9\u03c7\u03b5\u03af\u03b1<\/h2>\n
\u0394\u03bf\u03c3\u03bf\u03bb\u03bf\u03b3\u03af\u03b1 \u03ba\u03b1\u03b9 \u03a0\u03b1\u03c1\u03b1\u03ba\u03bf\u03bb\u03bf\u03cd\u03b8\u03b7\u03c3\u03b7<\/h2>\n
\u03a0\u03b1\u03c1\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b5\u03c2<\/h2>\n
\n
\u0391\u03bd\u03c4\u03b5\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2<\/h2>\n
\n
\u03a3\u03c5\u03c7\u03bd\u03ad\u03c2 \u0395\u03c1\u03c9\u03c4\u03ae\u03c3\u03b5\u03b9\u03c2<\/h2>\n
\u0397 \u03c0\u03bd\u03b5\u03c5\u03bc\u03bf\u03bd\u03b9\u03ba\u03ae \u03b1\u03c1\u03c4\u03b7\u03c1\u03b9\u03b1\u03ba\u03ae \u03c5\u03c0\u03ad\u03c1\u03c4\u03b1\u03c3\u03b7 \u03b5\u03af\u03bd\u03b1\u03b9 \u03c4\u03bf \u03af\u03b4\u03b9\u03bf \u03bc\u03b5 \u03c4\u03b7\u03bd \u201c\u03c5\u03c8\u03b7\u03bb\u03ae \u03b1\u03c1\u03c4\u03b7\u03c1\u03b9\u03b1\u03ba\u03ae \u03c0\u03af\u03b5\u03c3\u03b7\u201d;<\/h3>\n
Why does Rioci 1 require specialist monitoring?<\/h3>\n
Can I take Rioci 1 with erectile dysfunction drugs?<\/h3>\n
Can I take Rioci 1 in pregnancy?<\/h3>\n
Where can I buy Rioci 1 online?<\/h3>\n
\u03a3\u03c7\u03b5\u03c4\u03b9\u03ba\u03ac \u039a\u03b1\u03c1\u03b4\u03b9\u03b1\u03b3\u03b3\u03b5\u03b9\u03b1\u03ba\u03ac \u03a6\u03ac\u03c1\u03bc\u03b1\u03ba\u03b1<\/h2>\n
\n
\u03a3\u03c7\u03b5\u03c4\u03b9\u03ba\u03ad\u03c2 \u0395\u03bd\u03b1\u03bb\u03bb\u03b1\u03ba\u03c4\u03b9\u03ba\u03ad\u03c2<\/h3>\n
\n